Innoviva Inc (INVA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.35B
Last updated: Nov 17, 2026 at 11:06 AM ET
Innoviva Inc (INVA) Financials: Revenue, Profit and Cash Flow
Innoviva reported revenue of $411.33M for the fiscal year ended Dec 31, 2025, up 14.7% from the year before. That year, net income was $271.17M with a net margin of 65.9%, operating cash flow was $196.93M and free cash flow was $195.80M. The quarter ended Sep 30, 2026 had revenue of $106.12M and net income of -$73.89M.
Revenue and Margins
The operating margin was 39.8% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $133.57M, a compound annual rate of 13.3%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $411.33M | +14.7% | 74.8% | 39.8% | 65.9% |
| Dec 2024 | $358.71M | +15.5% | 82.6% | 46.5% | 6.5% |
| Dec 2023 | $310.46M | -6.3% | 79.2% | 36.7% | 57.9% |
| Dec 2022 | $331.34M | -15.4% | 95.8% | 96.7% | 66.5% |
| Dec 2021 | $391.87M | +16.4% | 100.0% | 119.0% | 94.1% |
| Dec 2020 | $336.79M | +29.0% | 100.0% | 110.3% | 87.2% |
| Dec 2019 | $261.02M | 0.0% | 100.0% | 94.4% | 73.2% |
| Dec 2018 | $261.00M | +20.2% | 100.0% | 91.3% | 155.7% |
| Dec 2017 | $217.22M | +62.6% | 100.0% | 84.5% | 61.8% |
| Dec 2016 | $133.57M | N/A | 100.0% | 81.6% | 89.1% |
Income Statement
In the fiscal year ended Dec 2025, net income rose 1059.3% from the year before. In the quarter ended Sep 2026, the company posted a net loss after a profit in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $411.33M | $358.71M | $310.46M | $331.34M | $391.87M | $336.79M | $261.02M | $261.00M | $217.22M | $133.57M |
| Cost of revenue | $103.66M | $62.50M | $64.42M | $13.79M | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $307.67M | $296.21M | $246.04M | $317.55M | $391.87M | $336.79M | $261.02M | $261.00M | $217.22M | $133.57M |
| Research and development | $30.60M | $13.65M | $33.92M | $41.43M | $576.00K | $1.79M | $0 | $0 | $1.35M | $1.39M |
| Operating income | $163.75M | $166.87M | $113.89M | $320.40M | $466.13M | $371.40M | $246.36M | $238.25M | $183.60M | $108.99M |
| Net income | $271.17M | $23.39M | $179.72M | $220.26M | $368.84M | $293.81M | $190.99M | $406.33M | $134.27M | $119.07M |
| EBITDA | $223.16M | N/A | $157.81M | $338.60M | $485.48M | $392.81M | $265.13M | $253.59M | $195.23M | $128.07M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $106.12M | $119.59M | $97.99M | $114.61M | $107.80M | $100.28M | $88.63M | $91.81M | $89.51M | $99.90M | $77.50M | $85.84M |
| Gross profit | $84.38M | $90.62M | $75.83M | $75.67M | $75.54M | $83.15M | $73.31M | $78.13M | $73.01M | $84.99M | $60.09M | $50.93M |
| Operating income | $42.15M | $50.85M | $38.15M | $38.99M | $34.58M | $48.75M | $41.43M | $43.14M | $43.24M | $54.69M | $25.80M | -$25.47M |
| Net income | -$73.89M | -$83.42M | $186.59M | $164.15M | $89.91M | $63.69M | -$46.58M | $20.33M | $1.21M | -$34.69M | $36.53M | $61.53M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded total debt of $258.15M by $292.79M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $1.64B | $1.30B | $1.24B | $1.23B | $926.39M | $999.57M | $724.83M | $548.19M | $367.34M | $379.00M |
| Current assets | $727.51M | $554.31M | $344.22M | $443.51M | $313.67M | $342.06M | $431.23M | $199.04M | $200.37M | $198.05M |
| Cash and equivalents | $550.94M | $304.96M | $193.51M | $291.05M | $201.53M | $246.49M | $278.10M | $62.42M | $73.34M | $118.02M |
| Total liabilities | $462.32M | $609.90M | $568.55M | $665.71M | $400.46M | $391.73M | $382.71M | $389.14M | $610.04M | $731.99M |
| Short-term debt | $418.00K | $192.03M | $0 | $96.19M | $0 | $25.00M | N/A | N/A | $25.00M | $7.75M |
| Long-term debt | $257.73M | $256.32M | $446.23M | $444.18M | $394.65M | $385.52M | $377.12M | $382.86M | $574.36M | $708.34M |
| Shareholder equity | $1.17B | $691.16M | $674.96M | $565.79M | $414.74M | $539.91M | $313.50M | $153.58M | -$242.86M | -$352.99M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $1.54B | $1.70B | $1.84B | $1.64B | $1.43B | $1.33B | $1.25B | $1.30B | $1.23B | $1.22B | $1.27B | $1.24B |
| Total liabilities | $400.41M | $469.46M | $494.93M | $462.32M | $419.15M | $618.75M | $607.49M | $609.90M | $563.07M | $559.40M | $563.93M | $568.55M |
| Cash and equivalents | $581.39M | $570.39M | $603.09M | $550.94M | $476.51M | $397.53M | $319.09M | $304.96M | $260.63M | $217.00M | $178.36M | $193.51M |
| Shareholder equity | $1.14B | $1.23B | $1.34B | $1.17B | $1.01B | $714.82M | $646.90M | $691.16M | $668.54M | $665.51M | $703.68M | $674.96M |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 99.4% of operating cash flow. Share repurchases came to 2.3% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $196.93M | $188.69M | $141.06M | $201.73M | $363.81M | $313.11M | $257.46M | $223.53M | $141.75M | $60.98M |
| Capital expenditures | $1.13M | $270.00K | $411.00K | $67.00K | $0 | $13.00K | $12.00K | $0 | $0 | $278.00K |
| Free cash flow | $195.80M | $188.42M | $140.65M | $201.66M | $363.81M | $313.10M | $257.45M | $223.53M | $141.75M | $60.71M |
| Dividends paid | N/A | N/A | $96.28M | $69.81M | $59.46M | $30.47M | $10.56M | $6.04M | $258.00K | $960.00K |
| Share repurchases | $4.53M | $14.78M | $75.73M | $8.50M | $394.15M | $0 | $0 | N/A | $97.50M | $78.09M |
| Investing cash flow | $40.50M | -$63.79M | -$66.76M | -$56.63M | $43.72M | -$314.94M | -$18.00M | $3.52M | -$23.24M | -$4.58M |
| Financing cash flow | $8.55M | -$13.45M | -$171.84M | -$55.57M | -$452.50M | -$29.79M | -$23.78M | -$237.97M | -$163.19M | -$97.57M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $41.70M | $51.97M | $35.28M | $54.51M | $49.73M | $44.07M | $48.62M | $59.24M | $48.69M | $43.72M | $37.05M | $33.26M |
| Capital expenditures | $24.00K | $429.00K | $492.00K | $10.00K | $1.12M | $0 | $0 | $4.00M | $270.00K | $0 | $0 | $151.00K |
| Free cash flow | $41.67M | $51.54M | $34.79M | $54.50M | $48.61M | $44.07M | $48.62M | $55.24M | $48.42M | $43.72M | $37.05M | $33.10M |
Frequently Asked Questions About INVA
What is Innoviva's annual revenue?
Innoviva reported revenue of $411.33M for the fiscal year ended Dec 31, 2025.
How fast is Innoviva's revenue growing?
Revenue was up 14.7% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 7.5%.
Is Innoviva profitable?
Yes. Innoviva reported net income of $271.17M for the fiscal year ended Dec 31, 2025, with a net margin of 65.9%.
How much free cash flow does INVA generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $196.93M minus capital expenditures of $1.13M produced free cash flow of $195.80M.
How much debt does Innoviva have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $257.73M, short-term debt of $418.00K and cash and equivalents of $550.94M.
INVA pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors